|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lamouille S, Subramanyam D, Blelloch R and
Derynck R: Regulation of epithelial-mesenchymal and
mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell
Biol. 25:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zaravinos A: The Regulatory Role of
MicroRNAs in EMT and Cancer. J Oncol. 2015:8658162015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li C, Song L, Zhang Z, Bai XX, Cui MF and
Ma LJ: MicroRNA-21 promotes TGF-β1-induced epithelial-mesenchymal
transition in gastric cancer through up-regulating PTEN expression.
Oncotarget. 7:66989–67003. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Zhang P, Sun X, Sun Y, Shi C, Liu H
and Liu X: MicroRNA-181a regulates epithelial-mesenchymal
transition by targeting PTEN in drug-resistant lung adenocarcinoma
cells. Int J Oncol. 47:1379–1392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brozovic A: The relationship between
platinum drug resistance and epithelial-mesenchymal transition.
Arch Toxicol. 91:605–619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang J, Li H and Ren G:
Epithelial-mesenchymal transition and drug resistance in breast
cancer (Review). Int J Oncol. 47:840–848. 2015.PubMed/NCBI
|
|
9
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:pii: E965. 2016. View Article : Google Scholar
|
|
10
|
Bugide S, Gonugunta VK, Penugurti V,
Malisetty VL, Vadlamudi RK and Manavathi B: HPIP promotes
epithelial-mesenchymal transition and cisplatin resistance in
ovarian cancer cells through PI3K/AKT pathway activation. Cell
Oncol. 40:133–144. 2016. View Article : Google Scholar
|
|
11
|
Chen GQ, Zhao ZW, Zhou HY, Liu YJ and Yang
HJ: Systematic analysis of microRNA involved in resistance of the
MCF-7 human breast cancer cell to doxorubicin. Med Oncol.
27:406–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou
H and Jia L: MicroRNA-130b targets PTEN to mediate drug resistance
and proliferation of breast cancer cells via the PI3K/Akt signaling
pathway. Sci Rep. 7:419422017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Q, Qin R, Fang Y and Li H: Berberine
sensitizes human ovarian cancer cells to cisplatin through
miR-93/PTEN/Akt signaling pathway. Cell Physiol Biochem.
36:956–965. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ke ZP, Xu P, Shi Y and Gao AM: MicroRNA-93
inhibits ischemia-reperfusion induced cardiomyocyte apoptosis by
targeting PTEN. Oncotarget. 7:28796–28805. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang L, Wang C, Lei F, Zhang L, Zhang X,
Liu A, Wu G, Zhu J and Song L: miR-93 promotes cell proliferation
in gliomas through activation of PI3K/Akt signaling pathway.
Oncotarget. 6:8286–8299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCann MJ, Rowland IR and Roy NC: The
anti-proliferative effects of enterolactone in prostate cancer
cells: Evidence for the role of DNA licencing genes, mi-R106b
cluster expression, and PTEN dosage. Nutrients. 6:4839–4855. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawano M, Tanaka K, Itonaga I, Ikeda S,
Iwasaki T and Tsumura H: microRNA-93 promotes cell proliferation
via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res.
34:762015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen J, Stass SA and Jiang F: MicroRNAs as
potential biomarkers in human solid tumors. Cancer Lett.
329:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
An X, Sarmiento C, Tan T and Zhu H:
Regulation of multidrug resistance by microRNAs in anti-cancer
therapy. Acta Pharm Sin B. 7:38–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Poliseno L, Salmena L, Riccardi L, Fornari
A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et
al: Identification of the miR-106b~25 microRNA cluster as a
proto-oncogenic PTEN-targeting intron that cooperates with
its host gene MCM7 in transformation. Sci Signal.
3:ra292010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petrocca F, Visone R, Onelli MR, Shah MH,
Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini
M, et al: E2F1-regulated microRNAs impair TGFbeta-dependent
cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell.
13:272–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gong C, Qu S, Liu B, Pan S, Jiao Y, Nie Y,
Su F, Liu Q and Song E: MiR-106b expression determines the
proliferation paradox of TGF-β in breast cancer cells. Oncogene.
34:84–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen S, Chen X, Xiu YL, Sun KX and Zhao Y:
Inhibition of ovarian epithelial carcinoma tumorigenesis and
progression by microRNA 106b mediated through the RhoC pathway.
PLoS One. 10:e01257142015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou Y, Hu Y, Yang M, Jat P, Li K,
Lombardo Y, Xiong D, Coombes RC, Raguz S and Yagüe E: The
miR-106b~25 cluster promotes bypass of doxorubicin-induced
senescence and increase in motility and invasion by targeting the
E-cadherin transcriptional activator EP300. Cell Death Differ.
21:462–474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Y, Li K, Asaduzzaman M, Cuella R, Shi
H, Raguz S, Coombes RC, Zhou Y and Yagüe E: MiR-106b~25 cluster
regulates multidrug resistance in an ABC transporter-independent
manner via downregulation of EP300. Oncol Rep. 35:1170–1178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kolacinska A, Morawiec J, Pawlowska Z,
Szemraj J, Szymanska B, Malachowska B, Morawiec Z,
Morawiec-Sztandera A, Pakula L, Kubiak R, et al: Association of
microRNA-93, 190, 200b and receptor status in core biopsies from
stage III breast cancer patients. DNA Cell Biol. 33:624–629. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McDermott AM, Miller N, Wall D, Martyn LM,
Ball G, Sweeney KJ and Kerin MJ: Identification and validation of
oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS
One. 9:e870322014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X,
Zhou C and Jiao D: Identification of microRNA-93 as a functional
dysregulated miRNA in triple-negative breast cancer. Tumour Biol.
36:251–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu S, Patel SH, Ginestier C, Ibarra I,
Martin-Trevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, et al:
MicroRNA93 regulates proliferation and differentiation of normal
and malignant breast stem cells. PLoS Genet. 8:e10027512012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh B, Ronghe AM, Chatterjee A, Bhat NK
and Bhat HK: MicroRNA-93 regulates NRF2 expression and is
associated with breast carcinogenesis. Carcinogenesis.
34:1165–1172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smith AL, Iwanaga R, Drasin DJ, Micalizzi
DS, Vartuli RL, Tan AC and Ford HL: The miR-106b-25 cluster targets
Smad7, activates TGF-β signaling, and induces EMT and tumor
initiating cell characteristics downstream of Six1 in human breast
cancer. Oncogene. 31:5162–5171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fang L, Du WW, Yang W, Rutnam ZJ, Peng C,
Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, et al: MiR-93
enhances angiogenesis and metastasis by targeting LATS2. Cell
Cycle. 11:4352–4365. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiang J, Fu X, Ran W and Wang Z: Grhl2
reduces invasion and migration through inhibition of TGFβ-induced
EMT in gastric cancer. Oncogenesis. 6:e2842017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dia VP and Pangloli P:
Epithelial-to-mesenchymal transition in paclitaxel-resistant
ovarian cancer cells is downregulated by luteolin. J Cell Physiol.
232:391–401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Preca BT, Bajdak K, Mock K, Lehmann W,
Sundararajan V, Bronsert P, Matzge-Ogi A, Orian-Rousseau V,
Brabletz S, Brabletz T, et al: A novel ZEB1/HAS2 positive feedback
loop promotes EMT in breast cancer. Oncotarget. 8:11530–11543.
2017.PubMed/NCBI
|
|
41
|
Liu G, Liu YJ, Lian WJ, Zhao ZW, Yi T and
Zhou HY: Reduced BMP6 expression by DNA methylation contributes to
EMT and drug resistance in breast cancer cells. Oncol Rep.
32:581–588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
